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ProtectionHere, we report a dual-route vaccination approach for plague, able to induce a rapid response involving
systemic and mucosal immunity, whilst also providing ease of use in those resource-poor settings most
vulnerable to disease outbreaks. This novel vaccine (VypVaxDuo) comprises the recombinant F1 and V
proteins in free association. VypVaxDuo has been designed for administration via a sub-cutaneous
priming dose followed by a single oral booster dose and has been demonstrated to induce early onset
immunity 14 days after the primary immunisation; full protective efficacy against live organism
challenge was achieved in Balb/c mice exposed to 2  104 median lethal doses of Yersinia pestis Co92,
by the sub-cutaneous route at 25 days after the oral booster immunisation. This dual-route vaccination
effectively induced serum IgG and serum and faecal IgA, specific for F1 and V, which constitute two key
virulence factors in Y. pestis, and is therefore suitable for further development to prevent bubonic plague
and for evaluation in models of pneumonic plague. This is an essential requirement for control of disease
outbreaks in areas of the world endemic for plague and is supported further by the observed exceptional
stability of the primary vaccine formulation in vialled form under thermostressed conditions (40 C for
29 weeks, and 40 C with 75% relative humidity for 6 weeks), meaning no cold chain for storage or dis-
tribution is needed.
In clinical use, the injected priming dose would be administered on simple rehydration of the dry
powder by means of a dual barrel syringe, with the subsequent single booster dose being provided in
an enteric-coated capsule suitable for oral self-administration.
Crown Copyright  2018 Published by Elsevier Ltd. This is an open access article under the Open
Government License (OGL) (http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/).1. Introduction
Plague is an ancient disease which is endemic today in many
global regions [1], with demonstrated potential for epidemic
spread. Indeed, one of the worst outbreaks, featuring a high rate
(70%) of confirmed and suspected pneumonic plague, occurred
from August–November 2017 in Madagascar [2], with >2500 cases
and a case fatality rate of 8.6% [2]. Whilst antibiotic therapy is
effective, this needs to be initiated early and is not ideal in a
plague-endemic area, because of the potential emergence ofanti-microbial resistance, as observed previously in Madagascar
and Peru [3,4].
Historically, research has shown that plague is preventable by
vaccination with live attenuated strains (EV76) or killed whole cell
vaccines (KWCV) [5]. Although EV76 vaccines are highly immuno-
genic, they also carry some risk [6]. The KWCV are hazardous to
produce and whilst thought effective against bubonic plague [7],
they are deficient against pneumonic plague [8]. Currently there
is no readily available licensed vaccine, although a variety of pla-
gue vaccine candidates have been proposed, reviewed in [9,10].
The F1 and V proteins have emerged as the predominant protective
antigens [11,12], whilst other proteins e.g. YscF [13], YadC and
OppA [14,15] have demonstrated partial efficacy. Previously, using
liquid formulations, we demonstrated that the recombinant F1 and
V proteins were safe and immunogenic in >160 volunteers [16] and
protective in a range of animal models of the disease [17,18]. The
induction of functional antibody [19] and cell-mediated immunity
[20] are both important for protection against plague.
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intended for emergency use authorisation (EUA) [21], inducing
rapid immunity and with simplified delivery involving an injected
prime and oral boost to induce systemic and mucosal immunity to
counter bubonic and pneumonic plague [22,23]. This vaccine
(VypVaxDuo) comprises two formulations: (i) F1 and V proteins
embedded in calcium phosphate coated onto amino-acid
microcrystals [24] for primary immunisation; and (ii) the same
antigens dispersed in an oil vehicle [25] for oral boosting. Our
aim is to provide an efficacious vaccine, easily administered in
resource-poor, low- to- middle income countries (LMIC), without
requirement for cold chain distribution or storage.
Here, each arm of the vaccination regimen has been optimised
for eventual clinical use, entailing the selection of excipients, par-
ticularly for the oral formulation, to overcome the tolerance which
protects humans from exposure to dietary antigens [26]. Enteric-
coating will ensure gastric transit; subsequent uptake by Peyer’s
Patches (PP) in the small intestine [27] will be promoted by incor-
porated excipients [28] such as vitamin A.D. and E derivatives,
which enhance dendritic cell (DC) activation, which in turn induces
effector T-cells [29,30]. Vitamin A or retinoic acid (RA) stimulates
gut-resident DC to induce T-cell expression of CCR9 and a4b7
[31] and promote gut-homing of T-cells through binding to
MAdCAM-1 and CCL25, selectively expressed on intestinal cells
[32]. Gut-resident DC also actively secrete RA, whilst skin-
resident DC produce the active form of vitamin D, 1,25(OH)2D3;
the latter imprints CCR10 expression on T-cells and homing to skin
inflammation sites through binding to CCL37, selectively expressed
on keratinocytes [33]. Alpha tocopheryl acetate (ATA), a non-toxic
derivative of vitamin E, also activates DC and has adjuvant
properties [34].Fig. 1. Immunogenicity of F1 + V in 3 dose (days 0, 10, 31) dual route schedule. Mice wer
the same formulation (s.c.) or with 25 mg F1 + 25 mg V in oil per oral (p.o.), with excipien
serum IgG and IgA titres per group to F1 (A) and (C) and to V (B) and (D) were determiWe have also incorporated dimethyldioctadecylammonium
bromide (DDAB), cholera toxin B sub-unit (CTB) and trehalose
dibehenate (TDB) in the oral formulation. DDAB is a cationic
surfactant with similar action to chitosan [35–37] promoting
electrostatic contact with PP cells and vaccine uptake. TDB, a syn-
thetic analog of the mycobacterial trehalose dimycolate, is a potent
macrophage activator [38], whilst CTB is anti-inflammatory and
immunomodulatory [39].
2. Materials and methods
2.1. Protein antigens, vaccine formulation and stability
Recombinant F1 and V antigens were expressed from E. coli,
purified as previously described [39] and supplied in PBS or
ammonium acetate buffer for formulation.
For initial sub-cutaneous (s.c.) testing, F1 and V were admixed
in PBS and MF59 (Novartis) was added 1:1 (v/v). For subsequent
studies, the injected formulations of F1 and V were prepared as cal-
cium phosphate microcrystals, using published methodology [24].
Briefly, aqueous mixtures of F1 and V with sodium orthophosphate
and glutamine (Gln) or histidine (His) were precipitated as calcium
phosphate protein-coated microcrystals (CaP-PCMC), by addition
into a 19- fold excess of isopropanol containing dissolved calcium
chloride. The resultant suspension contained self-assembled
microcrystals comprising an amino-acid core with the protein
embedded in a thin surface layer of CaP. The CaP-PCMC were iso-
lated by vacuum filtration and dried to a powder. Protein content
and integrity was determined by ELISA and SDS-Page.
The preparation of oral formulations of F1 and V was adapted
from published methodology [25]. In brief, F1 and V, dissolved ine administered 10 mg F1 + 10 mg V formulated in MF59 (s.c.) and boosted with either
ts as shown. Negative control mice received MF59 (s.c) on days 0, 10 and 31. Mean
ned at day 67.
Table 1
Immunogenicity of F1 + V in a 3 dose (days 0, 10, 31) dual route schedule. All priming
doses with F1 + V were administered s.c. in MF59; the formulations for oral booster
doses were varied in terms of different amphiphiles, oils, and immunostimulants. IgA
was measured on faecal pellets, collected at day 42 and amalgamated by treatment
group prior to extraction.
IgA measured in extracts
of faecal pellets (0.1 g),
amalgamated by
treatment group
Treatment groups F1 V
F1 + V/MF59 s.c./s.c 0 0
F1 + V/MF59 s.c./MO p.o. 6.3 3.02
F1 + V/MF59 s.c./MO + CTB p.o. 0 0
F1 + V/MF59 s.c./MO + DDAB p.o. 5.98 6.25
F1 + V/MF59 s.c./MO + ATAp.o. 8.29 2.18
Fig. 2A. Immunogenicity of F1 + V formulated on the same PCMC (F1 + V/Gln
PCMC) or on PCMC of different composition (F1/GlnPCMC + V/His PCMC), with and
without MF59, following immunisations in a 3 - dose s.c. only schedule (days 0, 10,
31) with 10 mg F1 + 10 mgV. Mean serum IgG titres to (A) F1 and (B) V were
determined at days 25 and 37.
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solution in cyclohexane, comprising a combination of soya phos-
phatidyl choline, Brij 52 and sodium docusate. This mixture was
vortexed to give a water-in-oil emulsion, cooled to 30 C and lyo-
philised overnight at 4 C. Next day, a clinical grade oil containing
the remaining excipients, was added to the dry residue. Iterations
of the oral formulation comprising either mineral oil (MO), M818
(Huls AG, Germany) or phytol and containing RA, ATA, vitamin D,
TDB (Invivogen, UK), CTB, and DDAB were prepared. All reagents
were purchased from Sigma-Aldrich UK, unless stated otherwise.
The optimum combination for efficacy testing comprised F1 and
V in MO with all the excipients above (termed Formulation B),
which was compared with Formulation A (identical, except for
the omission of CTB).
The formulations were subjected to a temperature range of
(4 C–40 C) for defined time periods and relative humidity (RH).
A relative humidity (RH) of 75% was maintained by using saturated
sodium chloride in a closed container housing samples in
screw-topped vials. Changes to F1 and V integrity were probed
by SDS-PAGE, size-exclusion chromatography--HPLC (SEC-HPLC)
and ELISA. SDS-Page gels were run under reducing conditions with
dithiothreitol (Sigma). Bolt 4–12% Bis-Tris Plus gels were used with
Bolt reagents and were silver-stained (Silver Xpress silver staining
kit). All electrophoresis reagents were obtained from ThermoFisher
Scientific.
2.2. Animals, immunisation, immunogenicity and efficacy
SPF female Balb/c mice (>6 weeks) were supplied by a commer-
cial breeder. Mice were randomised for allocation to treatment
group with food, water and environmental enrichment ad libitum
and acclimatised to the facility prior to any procedures, which
were performed in accordance with the UK Animal (Scientific Pro-
cedures) Act 1986. Mice were immunised in groups of 5 with either
(1): a s.c. priming dose followed either by two s.c. or two per oral
(p.o.) booster doses, given at 10 and 31 d. after the prime; or (2) a s.
c. priming dose followed by a single p.o. or s.c. booster dose
21 d. after the prime. For s.c. immunisation, mice received 10 mg
F1 + 10 mg V in 0.1 ml, whereas for p.o. dosing, mice received
25 mg F1 + 25 mg V in 0.1 ml, by gavage. For assay of antibody titre,
serial blood samples were collected from the tail vein, whilst final
samples were collected by cardiac puncture under terminal
anaesthesia. Faecal pellets were collected from each treatment
group and rapidly frozen (80 C).
F1- and V-specific serum IgG, IgA, IgG1 and IgG2a titres were
determined for individual mice by ELISA [40]. Faecal pellets (FP),
amalgamated by treatment group, were extracted for assay of
IgA. In brief, to 10 ml of cold PBS, 1 tablet of complete mini
protease inhibitor cocktail (Sigma) and 5 ml Tween 20 were added.
One ml of supplemented PBS was added per 0.1 g FP, incubated
(RT, 5 min), vortexed, incubated on ice (20 min) and centrifuged
(15,000g, 5 min). Supernatants were retained and stored at
80 C pending assay. Antibody concentrations were determined
from the standard curves included on each ELISA plate, using
Ascent software with four parameter logistic curve-fitting and
were reported in ng/ml or mg/ml of sample.
At 20 d. after the booster immunisation, mice were transferred
to ACDP3 biocontainment for live organism challenge and acclima-
tised in their treatment groups. Y. pestis Co92, a clinical isolate [41],
was cultured in blood agar broth and then diluted in PBS to esti-
mated challenge doses of 2  107/ml or 2  105/ml. The challenge
dose was quantified retrospectively by 48 h culture of the inocu-
lum on blood agar. Groups of mice were challenged with the
appropriate inoculum (0.1 ml/mouse s.c.) and then closely moni-
tored for 14d post-infection (p.i.), with those showing clinical signs
representing the humane endpoint, being culled by cervicaldislocation. At 14d p.i., surviving mice were terminally anaes-
thetised, blood was collected by cardiac puncture and mice were
culled, with splenectomy.
Splenocyte suspensions or sera were prepared in sterile PBS and
serially diluted; 0.1 ml of each suspension was cultured in dupli-
cate on blood agar (37 C, 48 h) before colony forming units
(CFU) were enumerated.
2.3. Statistical analysis
All data were analysed using Graph Pad Prism software v.6 and
expressed as mean ± s.e.m. Statistical comparisons were made
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expressed as Kaplan-Meier survival curves and statistical signifi-
cance was determined by Log-rank test. P < 0.05 was considered
statistically significant.3. Results
3.1. Vaccine formulation for dual route dosing
Initially, the formulation for the s.c. priming dose of F1 and V
was a simple mixture with MF59 adjuvant, whilst the formulation
for the oral booster doses (d.10 and 31) was varied in terms of
excipients and oil. The effect of varying the oral formulation on
serum IgG titres to F1 and V at the end of the immunisation sched-
ule (day 67) can be seen in Fig. 1 (Panels A-B). Oral boosting with
F1 + V formulated in MO with added CTB, significantly enhanced
IgG responses to F1 but not to V, compared with s.c. boosting with
F1 + V in MF59. Since MO was better tolerated by the mice than
either M818 or phytol, and since there was little advantage of these
alternative oil vehicles on IgG titres, MO was down selected for
subsequent studies. RA was also included, since similar IgG
responses were seen when presented in phytol, in the absence of
CTB.
Analysis of IgA in faecal extracts at d. 42 (11 d. after the oral
dose) indicated a benefit of including DDAB and ATA, but not
CTB, in the MO vehicle (Table 1). However, day 67 serum IgA titresFig. 2B. Determination of IgG isotypes induced to F1 and V at day 57, by PCMC formulatio
predominantly IgG1–biased (A and B) with some IgG2a (C and D) in the presence of MFfor each group primed with F1 + V/MF59 and boosted orally with
MO containing the individual immunostimulants (CTB/DDAB/
ATA) did not differ significantly from those achieved by s.c.
boosting (Fig. 1C and D). Intra-group, titres of serum IgA were more
variable than IgG. Since the excipients CTB, DDAB and ATA each
contribute differently to enhance immunity, and were compatible
in MO, they were combined into the oral formulation for
subsequent studies.3.2. Optimisation of the sub-cutaneous dosing formulation
For the s.c. arm of the dual route vaccine, permutations of F1
and V, either co-formulated on the same CaP-PCMC particle or
immobilised on separate particles, with or without MF59, were tri-
alled, initially in the 3-dose regimen (d.0,10,31) used above. The
development of specific IgG titres was determined at d. 25 and
57 (Fig. 2A). The absolute titre induced to the V antigen was greater
than that induced to the F1 antigen. However the specific titre to
either F1 or V, when both were formulated together on glutamine
PCMC (F1 + V/Gln), was significantly enhanced at d. 25 and 57 by
the addition of MF59. However, when different PCMC were used
F1 on Glutamine (F1/Gln) with V on Histidine (V/His) (F1/Gln + V
/His), only the response to V was significantly enhanced by the
inclusion of MF59.
At d. 57 of this s.c. dosing regimen, the predominant isotype to
either F1 or V, by 3 to 6-fold, was IgG1 (Fig. 2B). However, the addi-ns with and without MF59 in a 3 dose s.cutaneous only schedule (days 0, 10, 31) are
59.
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ticularly where F1 and V were presented together on the same glu-
tamine PCMC.
3.3. Optimisation of the dual route dosing regimen
Optimised formulations were combined in a dual route dosing
regimen. For the s.c. priming dose, F1/Gln + V/His PCMC ± MF59
were used. For the oral booster dose at day 21, F1 and V were com-
bined in formulation B. The serum IgG response was determined
after each dose at d.14 and 35 (Fig. 3A and B). In this dual route,
2-dose regimen, whilst the effect of adding MF59 to the s.c. prim-
ing dose was to reduce variability in the IgG response, it also lim-
ited the anti- F1 and V titres achieved at d.35, compared with
groups primed with the PCMC formulations without MF59 andFig. 3. Immunogenicity of F1 + V in dual route, 2- dose schedule (s.c. prime on day 0, with
14 (14 days after the primary immunisation) and day 35 (14 days after the oral booster).
35 after boosting with either of 2 different oral formulations (oral A or B) or not boostinboosted with oral formulation B. However when MF59 was
included in the priming formulation, it increased serum IgG2a rel-
ative to IgG1, so that the IgG1: IgG2a ratios were 28 and 20 for F1
and V respectively, whereas in the absence of MF59, serum IgG1
predominated, with IgG1: IgG2a ratios of 102 and 170 for F1 and
V (data not shown).
3.4. Characterisation of the effect of MF59 on the immune response to
F1 and V
The effect of MF59 in the priming formulation was investigated
in a subsequent study, in which mice were primed with PCMC ±
MF59 and either no booster dose, or one of two different oral for-
mulations (A or B) were administered. Here we again observed that
inclusion of MF59 in the priming formulation suppressed the anti-oral booster on day 21). Mean serum IgG titres are shown for F1 (A) and V (B) at day
In a subsequent study, mean serum IgA (C) and IgG (D) titres to F1 are shown at day
g.
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D); suppression of titre was independent of the exact oral formula-
tion used and was observed for the V antigen also (data not
shown).
From these studies, we selected candidate formulations for an
efficacy study: F1/Gln + V/His PCMC as the priming formulation;
formulation B for the oral booster.3.5. Protective efficacy against Y. pestis challenge
Mice immunised in the dual route dosing regimen on d. 0, 21
with F1/Gln + V/His PCMC s.c. and boosted orally with formulation
B, were challenged with Y. pestis Co92 by the s.c. route on d. 46
with 2.2  104 MLD (2.2  104 cfu) (Fig. 4). By d. 5p.i., all naïve
mice had died, whereas all immunised mice survived to d.14p.i.
In order to determine the limits of protective efficacy, 2 further
groups of mice were challenged on d.46 with 2.2  106 MLD
Y. pestis, and 90% survival was observed at 14 days p.i., with no
survivors in the naïve group. The blood and spleens of all mice
surviving at d.14p.i. were culture-negative for Y. pestis.Fig. 4. Protective efficacy of 2-dose dual route immunisation against live organism
challenge. Mice were immunised s.c. with the PCMC formulation on day 0 and
boosted with the oral formulation on day 21; they were challenged s.c. on day 46
with 2.2  104 cfu (2.2  104 MLD) Y. pestis Co92. The plot shows survival at day
14p.i.
Fig. 5A. Stability of CaP-PCMC samples after storage at 40 C for 29 weeks and analysis b
5 F1 stock 29 weeks at 40 C, Lane 6 blank, Lane 7 F1/Gln PCMC 29 weeks at 40 C, Lane3.6. Stability assessment
CaP-PCMC formulations held at 40 C for 29 weeks, were exam-
ined by SDS-Page (Fig. 5A). By comparison with unformulated
stock F1 and V (lanes 3 and 9) and thermo-stressed F1 stock (lane
5) and V (not shown) it is clear that theses unformulated ther-
mostressed proteins showed significant breakdown products. F1
and V proteins formulated on CaP PCMC (lanes 7 and 11) were sig-
nificantly more conserved after 29 weeks at 40 C, with heavy
bands at the expected positions (15 and 37 kDa respectively).
CaP PCMC formulated V and F1 were remarkably conserved after
storage for 6 weeks at both elevated temperature (40 C) and RH
(75%) lanes 6 (Fig. 5B, left and right panels) compared with fresh
stocks (lanes 3) and with PCMC formulations held for 6 weeks at
4 C (lanes 5).
Oral formulations which had been held at 4 C for 1 month, also
showed preservation of structure, when analysed by SEC-HPLC
(Supplemental Fig. 5C). The retention time of the F1 peak at
(3.11–3.16 min) remained consistent for consecutive samples
taken after 1, 2 or 4 weeks of storage. Similar data were obtained
for the V protein (not shown).
4. Discussion
We have successfully developed compatible formulations of F1
and V, for injected priming and oral boosting. This has involved for-
mulation optimisation, initially for individual vaccination routes.
For the primary vaccination, CaP-PCMC incorporating core glu-
tamine or histidine provide a matrix for presentation of the F1
and V proteins. For the oral booster, the F1 and V proteins were
incorporated into stable reverse micelles suspended in MO.
Used in a 2-dose dual route regimen, the oral formulation sig-
nificantly boosted F1- and V-specific serum IgG titres, achieving
values equivalent to those achieved initially with 3 injected doses.
This dual route approach induced both strong systemic and muco-
sal immune responses, which were rapid in onset. F1 and V-
specific circulating IgG was detectable at 14 days after the priming
dose, with specific IgA present in blood at 14 days after a singley SDS-PAGE. Lane 1 Mark 12 MWM, Lane 2 blank, Lane 3 fresh F1, Lane 4 blank, Lane
8 blank, Lane 9 fresh V, Lane 10 blank, Lane 11 V/His PCMC 29 weeks at 40 C.
Fig. 5B. Stability of CaP-PCMC samples after storage at 40 C/75%RH for 6 weeks and analysis by SDS-PAGE. Left panel: Lane 1 Mark 12 MWM, Lane 2 blank, Lane 3 fresh V
stock, Lane 4 blank, Lane 5 V/His PCMC 6 weeks at 4 C, Lane 6 V/His PCMC 6 weeks at 40 C/75%RH. Right panel: Lane 1 Mark 12 MWM, Lane 2 blank, Lane 3 fresh F1, Lane 4
Blank, Lane 5 F1/Gln PCMC 6 weeks at 4 C, Lane 6 F1/Gln PCMC 6 weeks at 40 C/75% RH.
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was gained from the detection of IgA in faecal extracts at day 42,
11 days after a second oral booster dose in mice immunised in
the interim 3-dose dual route regimen. It was important here to
determine the induction of mucosal as well as systemic immunity,
to justify subsequent testing of the vaccine in a pneumonic plague
model.
The systemic IgG response to the dual route vaccination, was
predominantly Th2- biased with high circulating levels of IgG1.
The inclusion of MF59 in the priming formulation reduced this
Th2 bias by inducing some IgG2a, reduced intra-group variability
but unexpectedly, also limited the response to the oral booster.
This differed from the adjuvantising effect of MF59 in the injected
3-dose regimen, where it significantly enhanced serum IgG titres.
These paradoxical effects of MF59 may be partly attributable to
the Th2-polarising effect of the oral booster curtailing the influence
of MF59 to induce Th1 responses, but we cannot rule out other
influences e.g. on antibody maturation and affinity. However,
because of its constraining effect on the response to the oral boos-
ter, MF59 was omitted from the final injected formulation.
The CaP PCMC is exceptionally stable, so that protein integrity
was maintained even after 29 weeks at 40 C and 75%RH. No dete-
rioration of protein in the oral formulation was observed over
1 month, albeit at 4 C. Once encapsulated, the anhydrous oral for-
mulation is also expected to withstand high ambient temperatures
and humidity, so that neither formulation will require cold chain
storage or distribution. In conclusion, we have developed a
2-dose, dual route vaccination regimen for plague and demon-
strated that this approach rapidly induces systemic and mucosal
immunity with high titres of specific IgG and detectable IgA in
blood and faecal extracts. We have demonstrated that this
approach is efficacious in a murine bubonic plague model at
25 d. after the booster dose and that survivors had no residual
bacteria. Work is ongoing to determine the limits of protective
efficacy for VypVaxDuo in pneumonic plague models.
Outbreaks of plague in endemic regions call for the approval of
an effective vaccine for EUA and a number of candidates including
VypVax Duo are in the research to clinical pipeline [9–11]. VypVax-
Duo represents a practical solution to vaccination in LMIC, since it
would require only one clinic visit to receive a priming dose and a
capsule, for self-administered oral boosting. This dual- route
dosing regimen provides a safe, stable, highly efficacious sub-unitvaccine for plague which promises to have significant impact on
disease burden in endemic areas.Acknowledgements
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